ReviewCancer medicine2024
The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer.
Review in Cancer medicine, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 22 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
22 citing papers in PubMed.
- Preclinical advances in glofitamab combinations: a new frontier for non-Hodgkin lymphoma.Blood · 2025Trial
- The closer, the better: intratumoral delivery of a thermoresponsive gemcitabine-loaded hydrogel in preclinical PDAC models.Drug delivery and translational research · 2026Article
- Screening the Combination of Gemcitabine, Clomipramine, and Resveratrol in HL-60 Leukemia Cells.Current issues in molecular biology · 2026Article
- A next-generation multimetal complex induces immunogenic cell death with distinct transcriptomic signatures.Chemical communications (Cambridge, England) · 2026Article
- Acetyl-L-carnitine protective role in gemcitabine-induced neurotoxicity in an experimental rat model.Open veterinary journal · 2026Article
- Syndecan-1-targeted therapeutic antibody impairs macropinocytosis and elicits antitumor immunity in pancreatic cancer.Cell reports. Medicine · 2026Article
- DNA damage response inhibitors in pancreatic cancer: progress and challenges.Frontiers in oncology · 2026Review
- Systemic Chemotherapy in Penile Squamous Cell Carcinoma: Mechanisms, Clinical Applications, and Evidence-Based Regimens.Cancers · 2025Review
- In Situ Vaccines in the Era of Cancer Immunotherapy: Conceptual Innovation and Clinical Translation.Advanced science (Weinheim, Baden-Wurttemberg, Germany) · 2025Review
- Reduction of resources with mRNA host-response whole blood testing on patients presenting to the emergency department with suspected infections: a retrospective analysis of 30 cases.Journal of medical microbiology · 2025Article
- Engineered exosomes: a promising approach for overcoming challenges in pancreatic cancer therapy.Journal of nanobiotechnology · 2025Review
- Chemoimmunotherapy synergism: mechanisms and clinical applications.Naunyn-Schmiedeberg's archives of pharmacology · 2025Review
- A novel cancer-associated membrane signature predicts prognosis and therapeutic response for lung adenocarcinoma.Scientific reports · 2025Article
- Intramolecular Versus Intermolecular Bonding in Drug Gemcitabine and Nucleobases: A Computational Study.Molecules (Basel, Switzerland) · 2025Article
- Anticancer Activity of Melittin-Containing Bee Venom Fraction Against Glioblastoma Cells In Vitro.International journal of molecular sciences · 2025Article
- CUB domain-containing protein 1 signaling dysregulates gemcitabine metabolism contributing to therapeutic resistance in T24 cells.PloS one · 2025Article
- Depletion of myeloid-derived suppressor cells alleviates kidney damage in murine membranous nephropathy.Frontiers in immunology · 2025Article
- Tailoring glioblastoma treatment based on longitudinal analysis of post-surgical tumor microenvironment.Journal of experimental & clinical cancer research : CR · 2024Article
- The double life of a chemotherapy drug: Immunomodulatory functions of gemcitabine in cancer.Cancer medicine · 2024Review
- Continuous Regression of Metastatic Pancreatic Adenocarcinoma after Suspending Chemotherapy: A Case Report.Case reports in oncologyArticle
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
Abstract
Although the development of immunotherapies has been revolutionary in the treatment of several cancers, many cancer types remain unresponsive to immune-based treatment and are largely managed by chemotherapy drugs. However, chemotherapeutics are not infallible and are frequently rendered ineffective as resistance develops from prolonged exposure. Recent investigations have indicated that some chemotherapy drugs have additional functions beyond their normative cytotoxic capacity and are in fact immune-modifying agents. Of the pharmaceuticals with identified immune-editing properties, gemcitabine is well-studied and of interest to clinicians and scientists alike. Gemcitabine is a chemotherapy drug approved for the treatment of multiple cancers, including breast, lung, pancreatic, and ovarian. Because of its broad applications, relatively low toxicity profile, and history as a favorable combinatory partner, there is promise in the recharacterization of gemcitabine in the context of the immune system. Such efforts may allow the identification of suitable immunotherapeutic combinations, wherein gemcitabine can be used as a priming agent to improve immunotherapy efficacy in traditionally insensitive cancers. This review looks to highlight documented immunomodulatory abilities of one of the most well-known chemotherapy agents, gemcitabine, relating to its influence on cells and proteins of the immune system.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.